Article
Genetic modifications of the adeno-associated virus type 2 capsid reduce the affinity and the neutralizing effects of human serum antibodies.
Gene therapy - 1 Dec 2003
Huttner N A, Girod A, Perabo L, Edbauer D, Kleinschmidt J A, Büning H, Hallek M
Abstract excerpt
The high prevalence of human serum antibodies against adeno-associated virus type 2 (AAV) vectors represents a potential limitation for in vivo applications. Consequently, the development of AAV vectors able to escape antibody binding and neutralization is of importance. To identify capsid domains which contain major immunogenic epitopes, six AAV capsid mutants carrying peptide insertions in surface exposed loop...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.